Epigenetic age testing
Epigenetic age testing uses DNA methylation patterns, via clocks such as Horvath, GrimAge, and DunedinPACE, to estimate biological age and pace of aging, a commercially fast-growing category led by providers like TruDiagnostic and Tally Health. The clocks correlate with mortality in retrospective cohorts, but clinical actionability remains the field's central open question. Evidence tier: emerging.
What it is
Epigenetic age testing estimates a person's biological age from patterns of DNA methylation, chemical modifications attached to DNA that change in measurable, age-correlated ways over the lifespan, distinct from the chronological age recorded on a birth certificate. The field originated with Steve Horvath's 2013 multi-tissue clock and has since produced successive generations of algorithms, including GrimAge and DunedinPACE, each trained to correlate methylation patterns more tightly with mortality and morbidity outcomes in retrospective cohort data. Commercially, providers process a saliva or blood sample through a methylation array and return a single number, biological age versus chronological age, sometimes alongside a pace-of-aging metric describing the rate of change over time. In the longevity economy, epigenetic age testing has become one of the most recognizable consumer-facing products in the diagnostics category, marketed as a way to quantify whether lifestyle or therapeutic interventions are measurably slowing aging. The framework is conceptually well-grounded in epigenetics research, and clock scores reliably correlate with age and, in several large cohorts, with future mortality risk, but the central open question, addressed below, is whether moving a clock score through intervention translates into a real change in health outcome.
Who it is for
Epigenetic age testing is positioned for longevity-engaged consumers and patients already pursuing other interventions, supplementation, exercise programs, or clinical protocols, who want a single quantified marker to track over time. It is also used by some clinics and research-adjacent programs as an outcome metric for marketing or internal evaluation of a protocol's apparent effect, though this use should be read with caution given the limitations described below.
What to expect
Epigenetic age testing is typically delivered as a direct-to-consumer or clinic-administered kit: a saliva swab or blood spot sample is collected, mailed to a laboratory for methylation array processing, and results are returned within two to four weeks as a biological age estimate, sometimes with a pace-of-aging score and trend tracking across repeat tests. Some providers bundle the test with a coaching call or report interpreting the score against lifestyle factors. In the Atlas, this recurs both as a dedicated consumer testing service (TruDiagnostic, Generation Lab, Tally Health) and as one component within broader longevity clinic diagnostic panels (Biongevity Clinic, The Apeiron Center), generally retested annually or after a defined intervention period.
History and background
The field traces to Steve Horvath's 2013 publication of a multi-tissue epigenetic clock built on DNA methylation data, followed by Horvath and Ake Lu's 2019 GrimAge clock, which improved correlation with mortality by training on surrogate biomarkers and time-to-death data rather than chronological age alone. Subsequent work, including the DunedinPACE algorithm published by groups associated with the long-running Dunedin longitudinal cohort study, shifted focus from a single age estimate toward measuring the pace of biological aging over a defined window. Commercial epigenetic testing entered the consumer market in the late 2010s and expanded rapidly through the early 2020s, with TruDiagnostic emerging as one of the larger direct-to-consumer providers and a frequent data partner for academic clock-validation research.
Worth knowing
Different epigenetic clocks can produce meaningfully different biological age estimates for the same person, since each algorithm is trained on different reference data and outcome targets, a source of confusion for consumers comparing results across providers. Several published intervention studies have reported measurable shifts in epigenetic age following lifestyle or pharmacological protocols, but whether those shifts predict actual changes in disease risk or lifespan in the people tested remains unproven, the field's central unresolved question. Within the Atlas, epigenetic age testing links to seven entities, just short of the stricter linkage threshold applied elsewhere in this directory, but it is included in Phase 1 because the category sits at the center of how the longevity industry talks about measuring its own results.
Offered across the Atlas 7
Related modalities